Elise J Barney
- Associate Clinical Professor, Internal Medicine - (Clinical Series Track)
- Assistant Clinical Professor, Internal Medicine
- Director, Cardiovascular and Hematology Systems (CVH) Block
- Co-Director, Gastrointestinal/Diabetes/Metabolism (GIMDO) Block
- (602) 827-2002
- COLLEGE OF MEDICINE PHX
- PHOENIX, AZ 85004-2230
- ejbarney@arizona.edu
Biography
Elise J. Barney, D.O., is a Clinical Assistant Professor at the University of Arizona College of Medicine-Phoenix (UACOM-Phoenix) and a practicing nephrologist. Dr. Barney is a clinician educator and her work is focused on innovative education with a student-centered approach. Dr. Barney is the Director of the Cardiovascular and Hematological systems (CVH) Block and Co-Director of the GI-Metabolism-Diabetes-Nutrition block and currently teaches in various areas, including nutrition, diabetes, eating disorders, electrolytes and fluid balance for the pre-clerkship curriculum as well as nephrology topics at BUMC Internal Medicine residency program. Her teaching approach focuses on a solid foundational understanding of pathophysiology and mechanisms of disease. She is a member of the Curriculum Committee and Women in Medicine and Science (WIMS) at UACOM-Phoenix. Her service work includes volunteering at the UACOM student-led PACH Clinic, student advising for the Migrant Health Interest Group, and serving on the board for Pre-Health Shadowing organization. She is also a mentor to students and supervisor for an MS1 Scholarly Project and an MS2 research project involving medical education in the CVH block.
Degrees
- D.O. Osteopathic Medicine
- Midwestern University / Arizona College of Osteopathic Medicine, Glendale, Arizona, United States
Work Experience
- Regional West Medical Center (2020 - Ongoing)
- Phoebe Putney Healthcare System (2020 - Ongoing)
- Billings Clinic (2020 - Ongoing)
- Yuma Regional Medical Center (2020 - Ongoing)
- Rosewood Center for Eating Disorders (2018 - 2020)
- Phoenix VA Healthcare system (2015 - 2018)
- Southwest Kidney Institute (2013 - 2015)
- Phoenix Indian Medical Center (2011 - Ongoing)
Awards
- Excellence in Teaching in a Block - GIMDN Block
- UACOM-P, Summer 2024
- Educator of the Year
- UACOM-P, Spring 2024 (Award Nominee)
- Gold Humanism Honor Society Inductee
- Spring 2023
- Gold Humanism Society
- Spring 2023
- MS2 Educator of the Year Award
- Summer 2022
Licensure & Certification
- Medical License, Arizona Board of Osteopathic Medicine (2007)
- Board Certification in Internal Medicine, American Board of Internal Medicine (2011)
- Board Certification in Nephrology, American Board of Internal Medicine (2015)
Interests
Teaching
Nephrology, Hypertension, Nutrition/Eating Disorders
Research
Acute kidney injury, Glomerular disease
Courses
2024-25 Courses
-
Cardiovascular Hematology
MEDP 806 (Spring 2025) -
GIMDN
MEDP 810 (Fall 2024)
2023-24 Courses
-
Cardiovascular Hematology
MEDP 806 (Spring 2024) -
GIMDN
MEDP 810 (Fall 2023)
2022-23 Courses
-
Cardiovascular Hematology
MEDP 806 (Spring 2023) -
GIMDN
MEDP 810 (Fall 2022)
2021-22 Courses
-
Cardiovascular Hematology
MEDP 806 (Spring 2022) -
GIMDN
MEDP 810 (Fall 2021)
2020-21 Courses
-
Cardiovascular Hematology
MEDP 806 (Spring 2021) -
Principles of CVH
MEDP 620 (Spring 2021)
2019-20 Courses
-
Cardiovascular Hematology
MEDP 806 (Spring 2020)
Scholarly Contributions
Journals/Publications
- Barney, E. J., Little, E. C., Gerkin, R. D., Ramos, A. X., Kahn, J., Wong, M., Kolli, G., & Manch, R. (2012). Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis.. Digestive diseases and sciences, 57(9), 2430-7. doi:10.1007/s10620-012-2162-zMore infoThrombocytopenia is a common complication of chronic liver disease. The theory of portal decompression to improve thrombocytopenia due to hypersplenism has led to the study of transjugular intrahepatic portosystemic shunt (TIPS) as a potential therapy. However, there is a paucity of data and results have been conflicting. The aim of this study was to determine whether platelet counts improved in cirrhotic patients after placement of the new polytetrafluoroethylene (PTFE)-coated TIPS, developed in 2004..This is a retrospective cohort study of 68 patients with chronic liver disease who underwent a TIPS procedure. One-hundred twenty controls who did not undergo a TIPS procedure were matched on average for age, sex, race, model for end-stage liver disease (MELD) score, and etiology of liver disease. Platelet and hemoglobin counts were recorded during the month prior to the TIPS procedure (baseline) and over the following 12-14 months or until transplanted or death..While platelet counts improved during the first 3 months after TIPS with a mean increase of 11.25 × 103/μL (p = 0.064), they returned to baseline (pre-TIPS) with mean platelets of 91.31 × 103 μL by 12-14 months in comparison with a mild decrease of 10.2 × 103 μL in platelet counts in the control group from 100.4 × 103 μL to 90.2 × 103 (p = 0.119). There was also no significant correlation between platelet counts and etiology of liver disease, age, race, gender, or MELD score. Hemoglobin counts were found to have a small increase of 0.657 g/dL over the 12-14 month course in the TIPS group, which was statistically significant (p = 0.003)..There does not appear to be a significant improvement in thrombocytopenia in cirrhotic patients after TIPS placement, despite advances in TIPS stents. However, there may be a mild improvement in anemia after TIPS implantation.
Poster Presentations
- Barney, E. J. (2020, 10/Fall). Collapsing FSGS in Covid-19. American Society of Nephrology Annual Kidney Week Conference. Virtual Conference due to Covid-19.
